Next-week's presentation is another smokescreen for Leo's inability to land a partner or new financial deal... Funding slowly running dry, so the pressure builds into Q-4... Finally, Leo has to produce either a partnership or Aspire-like extension or it's game over...
"Second, the Company will be presenting topline findings from the Brilacidin-UP/UPS trial as well as additional interim data from its Phase 2 trial of Brilacidin for Oral Mucositis at Drug Discovery and Therapy World Congress 2017, to be held July 10 – 13, 2017, in Boston. More details to come."
The conference abstract discusses 19 OM patients. If they were going to provide data on any additional patients wouldn't it be included in the abstract ?